Author

Sara Lavoie

Observed names: Lavoie, Sara, S Lavoie

Institution: Moderna Therapeutics (United States)

Observed institution: Moderna Therapeutics (United States)

ORCID: 0000-0003-4561-4746

Observed ORCID: 0000-0003-4561-4746

OpenAlex ID: A5090236759

The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis

2019 · Dennis A. Revicki, Rebecca M. Speck, et al. · Neurogastroenterology & Motility · 32

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)

2018 · Asha Hareendran, Anne Skalicky, et al. · Headache The Journal of Head and Face Pain · 32

Radionuclide esophageal transit in progressive systemic sclerosis.

1985 · S Carette, Y Lacourciere, et al. · PubMed · 27

The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis

2018 · Dennis A. Revicki, Sara Lavoie, et al. · Journal of Patient-Reported Outcomes · 18

767 Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma

2022 · Daniel Olson, Adil Daud, et al. · Regular and Young Investigator Award Abstracts · 5

Mo1588 – Increased Symptom Severity Associated with the Reduction in Health-Related Quality of Life in Patients with Idiopathic Or Diabetic Gastroparesis

2019 · Dennis Revicki, Rebecca Speck, et al. · Gastroenterology

Works count: 8

Citation count: 114

H-index: 5

I10-index: 4